Cargando…
Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe adm...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356893/ https://www.ncbi.nlm.nih.gov/pubmed/32492927 http://dx.doi.org/10.3390/jcm9061675 |
_version_ | 1783558587343175680 |
---|---|
author | Yamaguchi, Satoshi Oba, Kageyuki Higa, Moritake Arasaki, Osamu Shimabukuro, Michio |
author_facet | Yamaguchi, Satoshi Oba, Kageyuki Higa, Moritake Arasaki, Osamu Shimabukuro, Michio |
author_sort | Yamaguchi, Satoshi |
collection | PubMed |
description | Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe administration in Japanese patients with or without type 2 diabetes mellitus (T2DM). This single-center retrospective observational study enrolled a total of 266 consecutive ezetimibe-naïve patients, of which 154 were excluded because of either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To identify the factors influencing LDL-C levels, univariate and multivariate linear regression analyses were performed after 52 weeks of ezetimibe treatment. Overall, advanced age, T2DM, and high baseline LDL-C were significantly associated with a greater decrease in LDL-C levels. In the non-T2DM group, advanced age and high baseline LDL-C were associated with greater decrease in LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that influenced the change in LDL-C levels. Advanced age was significantly associated with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. Ezetimibe use might be beneficial in older patients without T2DM. The lack of association between age and the LDL-C lowering effect by ezetimibe in patients with T2DM may be due to yet unknown mechanism except low statistical power. |
format | Online Article Text |
id | pubmed-7356893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73568932020-07-22 Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus Yamaguchi, Satoshi Oba, Kageyuki Higa, Moritake Arasaki, Osamu Shimabukuro, Michio J Clin Med Article Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe administration in Japanese patients with or without type 2 diabetes mellitus (T2DM). This single-center retrospective observational study enrolled a total of 266 consecutive ezetimibe-naïve patients, of which 154 were excluded because of either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To identify the factors influencing LDL-C levels, univariate and multivariate linear regression analyses were performed after 52 weeks of ezetimibe treatment. Overall, advanced age, T2DM, and high baseline LDL-C were significantly associated with a greater decrease in LDL-C levels. In the non-T2DM group, advanced age and high baseline LDL-C were associated with greater decrease in LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that influenced the change in LDL-C levels. Advanced age was significantly associated with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. Ezetimibe use might be beneficial in older patients without T2DM. The lack of association between age and the LDL-C lowering effect by ezetimibe in patients with T2DM may be due to yet unknown mechanism except low statistical power. MDPI 2020-06-01 /pmc/articles/PMC7356893/ /pubmed/32492927 http://dx.doi.org/10.3390/jcm9061675 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yamaguchi, Satoshi Oba, Kageyuki Higa, Moritake Arasaki, Osamu Shimabukuro, Michio Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus |
title | Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus |
title_full | Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus |
title_fullStr | Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus |
title_full_unstemmed | Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus |
title_short | Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus |
title_sort | age-dependent efficacy of ezetimibe for low-density lipoprotein cholesterol reduction in japanese patients with or without type 2 diabetes mellitus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356893/ https://www.ncbi.nlm.nih.gov/pubmed/32492927 http://dx.doi.org/10.3390/jcm9061675 |
work_keys_str_mv | AT yamaguchisatoshi agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus AT obakageyuki agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus AT higamoritake agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus AT arasakiosamu agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus AT shimabukuromichio agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus |